A PHASE 1 RANDOMIZED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO EXAMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF CP12 IN HEALTHY AD
$2,194,516FY2018Department of the ArmyDOD
Cal Enterprises, Llc
Investigators
View source on USAspending →A PHASE 1 RANDOMIZED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO EXAMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF CP12 IN HEALTHY AD · GrantIndex